Li Watsek
Stock Analyst at Cantor Fitzgerald
(1.21)
# 3,470
Out of 4,847 analysts
74
Total ratings
38.96%
Success rate
-21.89%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Li Watsek
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASND Ascendis Pharma | Reiterates: Overweight | $200 | $174.40 | +14.68% | 18 | May 12, 2025 | |
| ZLAB Zai Lab | Reiterates: Overweight | n/a | $31.13 | - | 1 | Mar 27, 2025 | |
| ACRV Acrivon Therapeutics | Reiterates: Overweight | n/a | $1.16 | - | 2 | Mar 26, 2025 | |
| TARA Protara Therapeutics | Initiates: Overweight | n/a | $3.29 | - | 1 | Mar 14, 2025 | |
| ARVN Arvinas | Reiterates: Overweight | n/a | $7.00 | - | 5 | Feb 7, 2025 | |
| ALXO ALX Oncology Holdings | Reiterates: Overweight | n/a | $0.55 | - | 7 | Jan 24, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Overweight | n/a | $21.64 | - | 2 | Jan 13, 2025 | |
| KURA Kura Oncology | Reiterates: Overweight | n/a | $6.42 | - | 10 | Dec 9, 2024 | |
| RCUS Arcus Biosciences | Reiterates: Overweight | n/a | $10.03 | - | 4 | Oct 7, 2024 | |
| YMAB Y-mAbs Therapeutics | Reiterates: Overweight | $20 | $4.88 | +309.84% | 2 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $8.30 | - | 5 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.30 | - | 1 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $4.12 | - | 5 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.64 | +82.93% | 4 | Nov 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $220 | $7.71 | +2,753.44% | 3 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $1.36 | +267.65% | 3 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $38 | $1.77 | +2,046.89% | 1 | Aug 12, 2022 | |
Ascendis Pharma
May 12, 2025
Reiterates: Overweight
Price Target: $200
Current: $174.40
Upside: +14.68%
Zai Lab
Mar 27, 2025
Reiterates: Overweight
Price Target: n/a
Current: $31.13
Upside: -
Acrivon Therapeutics
Mar 26, 2025
Reiterates: Overweight
Price Target: n/a
Current: $1.16
Upside: -
Protara Therapeutics
Mar 14, 2025
Initiates: Overweight
Price Target: n/a
Current: $3.29
Upside: -
Arvinas
Feb 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $7.00
Upside: -
ALX Oncology Holdings
Jan 24, 2025
Reiterates: Overweight
Price Target: n/a
Current: $0.55
Upside: -
IDEAYA Biosciences
Jan 13, 2025
Reiterates: Overweight
Price Target: n/a
Current: $21.64
Upside: -
Kura Oncology
Dec 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $6.42
Upside: -
Arcus Biosciences
Oct 7, 2024
Reiterates: Overweight
Price Target: n/a
Current: $10.03
Upside: -
Y-mAbs Therapeutics
Sep 9, 2024
Reiterates: Overweight
Price Target: $20
Current: $4.88
Upside: +309.84%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $8.30
Upside: -
May 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.30
Upside: -
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $4.12
Upside: -
Nov 22, 2023
Reiterates: Overweight
Price Target: $3
Current: $1.64
Upside: +82.93%
Sep 7, 2023
Reiterates: Overweight
Price Target: $220
Current: $7.71
Upside: +2,753.44%
Sep 7, 2023
Reiterates: Neutral
Price Target: $5
Current: $1.36
Upside: +267.65%
Aug 12, 2022
Maintains: Overweight
Price Target: $60 → $38
Current: $1.77
Upside: +2,046.89%